The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined with MKC-442 in HIV-Infected Patients Who Have Not Had Success with Protease Inhibitors
Information source: Bristol-Myers Squibb
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: HIV Infections
Intervention: Emivirine (Drug); Hydroxyurea (Drug); Nevirapine (Drug); Stavudine (Drug); Didanosine (Drug)
Phase: Phase 2
Sponsored by: Boehringer Ingelheim Pharmaceuticals
The purpose of this study is to see if it is safe and effective to give a new anti-HIV drug
combination to HIV-infected patients who have never taken nonnucleoside reverse transcriptase
inhibitors (NNRTIs) and who have failed to respond to protease inhibitors (PIs). The drug
combination will contain didanosine (ddI) plus stavudine (d4T) plus nevirapine (NVP) plus
MKC-442. Hydroxyurea (HU) may be added.
Official title: A Phase II, 24-Week, Open-Label Study Designed to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Novel Combination Therapy with Videx (Didanosine), Zerit (Stavudine), Viramune (Nevirapine), and MKC-442 (with or without Hydroxyurea) for the Treatment of HIV-1 Infection in Non-Nucleoside Reverse Transcriptase Inhibitor Naive Patients Who Failed Previous Protease Inhibitor Treatment
Study design: Treatment, Pharmacokinetics Study
Patients receive a regimen of didanosine, stavudine, nevirapine, and MKC-442 for 24 weeks.
Throughout the study, patients are evaluated for changes from baseline in plasma HIV-1 RNA
levels and lymphocyte subsets and for development of adverse events and toxicities. Patients
who experience virologic failure have the option of adding hydroxyurea to their treatment
regimen or discontinuing from the study. After Week 24, patients with documented virologic
response may continue treatment with didanosine, stavudine, nevirapine, and MKC-442, and, if
applicable, hydroxyurea until a change in virologic status occurs (i. e., the patient
experiences virologic failure). Follow-up visits are conducted every 4 to 12 weeks until
permanent discontinuation from the study.
Minimum age: 18 Years.
Maximum age: N/A.
You may be eligible for this study if you:
- Are at least 18 years old.
- Are HIV-positive.
- Have experienced treatment failure on a previous anti-HIV drug combination that
contained at least one protease inhibitor. Your viral load must be between 5,000 and
50,000 copies/ml after 6 months of continuous treatment with that drug combination.
- Agree to use a barrier method of birth control (such as condoms) during the study.
You will not be eligible for this study if you:
- Have a history of certain serious medical conditions, including pancreatitis,
neuropathy, untreated seizures, or AIDS-related cancers, except Kaposi's sarcoma
- Are enrolled in another anti-HIV drug study while participating in this study.
- Have ever taken NNRTIs (such as NVP or MKC-442).
- Have ever taken ddI or d4T.
- Have taken certain medications within 30 days prior to study entry, including
medications that affect your immune system (such as corticosteroids, interleukin-2, or
- Abuse alcohol or drugs.
- Have received chemotherapy or radiation therapy within 30 days prior to study entry.
(Local radiation therapy is allowed.)
- Are allergic to any of the study drugs.
- Are pregnant or breast-feeding.
Locations and Contacts
Pacific Oaks Med Group, Beverly Hills, California 90211, United States
Univ of Colorado / Health Science Ctr, Denver, Colorado 80262, United States
AIDS Research Consortium of Atlanta, Atlanta, Georgia 30308, United States
Brown Univ School of Medicine, Providence, Rhode Island 02908, United States
Hampton Roads Med Specialists, Hampton, Virginia 23666, United States